Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $81.52M.
ENTERPRISE VALUE (EV)
$81.52M
Voyager Therapeutics, Inc.
Market Cap
$146.82M
Enterprise Value (EV)
$81.52M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | $146.82M | $81.52M |
| Codexis, Inc. (CDXS)vs › | $146.82M | $192.24M |
| ALX Oncology Holdings Inc. (ALXO)vs › | $147.35M | $134.36M |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.26M | $118.39M |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.96M | $27.63M |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $145.70M | $84.50M |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.68M | $144.29M |
| Protara Therapeutics, Inc. (TARA)vs › | $145.29M | $130.96M |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | $12.27M |
| Veraxa Biotech Holding AG (VRXA)vs › | $151.28M | N/A |
Market Cap
$146.82M
Total Debt
$0.00
Cash
$65.30M
Enterprise Value
$81.52M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
